Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device.
Creinin MD, Gawron LM, Roe AH, Blumenthal PD, Boraas CM, Hou MY, McNicholas C, Schreifels MJ, Peters K, Culwell K, Turok DK; Copper 175mm2 IUD Phase 3 Clinical sInvestigator Group.
Creinin MD, et al. Among authors: gawron lm.
Contraception. 2024 Nov 22:110771. doi: 10.1016/j.contraception.2024.110771. Online ahead of print.
Contraception. 2024.
PMID: 39581486